1.345USD-0.37%Mkt Cap: 50.82M USDP/E: —Last update: 2026-05-26
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long prote…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap50.82M USD
Enterprise Value-51.66M USD
Revenue (TTM)22.33M USD
Gross Profit-72.10M USD
Net Income (TTM)-87.87M USD
Revenue/Share0.5970 USD
Last Price1.345 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees119
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.89
PEG—
EV/EBITDA0.59
EV/Revenue-2.31
P/S2.21
P/B0.36
EPS (TTM)-2.29
EPS (Forward)-1.47
52W Range
1.2404% of range3.950
52W High3.950 USD
52W Low1.240 USD
Profitability
Gross Margin0.00%
Oper. Margin-1970.11%
EBITDA Margin0.00%
Profit Margin-348.54%
ROE-55.40%
ROA-39.74%
Growth
Revenue Growth-69.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.89M USD
CapEx (TTM)574.00K USD
FCF Margin-252.02%
FCF Yield-110.73%
Net Debt-100.98M USD
Net Debt/EBITDA1.15
Balance Sheet
Debt/Equity0.26
Current Ratio6.42
Quick Ratio6.23
Book Value/Sh3.660 USD
Cash/Share3.723 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)8.000 USD
Target Range7.000 USD – 9.000 USD
# Analysts2
Ownership
Shares Out.37.65M
Float27.35M
Insiders19.25%
Institutions19.32%
Short Interest
Short Ratio9.7d
Short % Float5.86%
Short % Out.4.75%
Shares Short1.79M
Short (prev mo.)2.17M
Technical
SMA 501.400 (-3.9%)
SMA 2001.798 (-25.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)180.60K
Avg Vol (10d)209.49K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—